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Abstract
Background: There is evidence that physical activity (PA) can attenuate the influence of the fat mass- and obesity-associated
(FTO) genotype on the risk to develop obesity. However, whether providing personalized information on FTO genotype leads
to changes in PA is unknown.
Objective: The purpose of this study was to determine if disclosing FTO risk had an impact on change in PA following a
6-month intervention.
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Methods: The single nucleotide polymorphism (SNP) rs9939609 in the FTO gene was genotyped in 1279 participants of the
Food4Me study, a four-arm, Web-based randomized controlled trial (RCT) in 7 European countries on the effects of personalized
advice on nutrition and PA. PA was measured objectively using a TracmorD accelerometer and was self-reported using the Baecke
questionnaire at baseline and 6 months. Differences in baseline PA variables between risk (AA and AT genotypes) and nonrisk
(TT genotype) carriers were tested using multiple linear regression. Impact of FTO risk disclosure on PA change at 6 months
was assessed among participants with inadequate PA, by including an interaction term in the model: disclosure (yes/no) × FTO
risk (yes/no).
Results: At baseline, data on PA were available for 874 and 405 participants with the risk and nonrisk FTO genotypes, respectively.
There were no significant differences in objectively measured or self-reported baseline PA between risk and nonrisk carriers. A
total of 807 (72.05%) of the participants out of 1120 in the personalized groups were encouraged to increase PA at baseline.
Knowledge of FTO risk had no impact on PA in either risk or nonrisk carriers after the 6-month intervention. Attrition was higher
in nonrisk participants for whom genotype was disclosed (P=.01) compared with their at-risk counterparts.
Conclusions: No association between baseline PA and FTO risk genotype was observed. There was no added benefit of disclosing
FTO risk on changes in PA in this personalized intervention. Further RCT studies are warranted to confirm whether disclosure
of nonrisk genetic test results has adverse effects on engagement in behavior change.
Trial Registration: ClinicalTrials.gov NCT01530139; http://clinicaltrials.gov/show/NCT01530139 (Archived by WebCite at:
http://www.webcitation.org/6XII1QwHz)
(J Med Internet Res 2016;18(2):e30)   doi:10.2196/jmir.5198
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Introduction
The prevalence of physical inactivity in Europe and worldwide
is high [1]. Given that physical inactivity is among the top risk
factors for noncommunicable diseases [2], finding effective
ways to achieve long-lasting improvements in physical activity
(PA) remains a major challenge [3]. While previous intervention
strategies have mainly focused on a "one-size-fits-all" approach
to change behavior, recent studies have used personalized
approaches, such as tailored Web-based interventions [4,5].
There is inconsistent evidence on whether these personalized
approaches are more effective at increasing PA than standard
guidelines, and effects, when present, are often small and with
short-term efficacy [6]. Concurrently, there has been a growing
interest in using genetic information to personalize lifestyle
interventions [7]. Although disclosure of such information does
not appear to have unintended adverse effects, more randomized
controlled trials (RCTs) are needed to establish whether
gene-based personalized interventions promote greater behavior
change than conventional "one-size-fits-all" interventions [8].
In particular, data on whether providing genetic information
leads to an increase in PA are lacking.
The fat mass- and obesity-associated (FTO) gene has provided
strong evidence of the genetic susceptibility to obesity.
Polymorphisms in this gene located in intron 1 and exon 2 have
been shown to be consistently and strongly associated with
obesity-related markers [9,10]. For instance, individuals
homozygous for the higher-risk allele, AA, of single nucleotide
polymorphism (SNP) rs9939609 in the FTO gene FTO weighed,
on average, 3 kg more and had 1.7-fold increased odds of having
obesity compared with those homozygous for the lower-risk
allele, TT [11]. Moreover, there is increasing evidence that the
FTO genetic susceptibility to obesity can be modulated by
lifestyle factors, and that PA, for example, may attenuate the
effects of the FTO genotype on obesity-related traits [12-17].
However, to our knowledge there is no data on whether
disclosing information on FTO genotype can motivate
individuals to increase their PA. Elucidating whether
genetic-based advice can promote improvements in PA
behaviors may help in the design of more effective interventions,
especially when tailored to individuals who would benefit most
from increasing their PA.
As part of the Food4Me study (ClinicalTrials.gov number:
NCT01530139)—a Web-based RCT in 7 European
countries—we investigated the effects of 3 levels of personalized
advice on changes in PA, including a level with genetic
information on FTO [18,19]. See Multimedia Appendix 1 for
the CONSORT-EHEALTH checklist [20]. We found that
personalized feedback in general led to greater improvements
in self-reported PA, but not in objectively measured PA,
compared with standard guidelines [19]. However, we did not
investigate the effect of disclosing genetic-based information
on PA change, and whether the response differs between carriers
of a genetic risk and nonrisk carriers. Thus, the aim of these
analyses was to assess the impact of knowledge of FTO risk
status on change in self-reported and objectively measured PA
in Food4Me participants.
Methods
Subjects
Subjects were participants of the Food4Me study, a 6-month,
Web-based RCT on personalized nutrition and lifestyle
conducted in 7 European countries—Germany, Greece, Ireland,
the Netherlands, Poland, Spain, and the United Kingdom. As
outlined elsewhere [18], 1607 adults aged ≥18 years were
randomized to the study. Exclusion criteria included no or
limited access to the Internet, following a prescribed diet, or
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having altered nutritional requirements because of a medical
condition. The local ethics committee of each recruiting center
approved the study protocol and all subjects provided informed
consent digitally before participating.
Study Design
Participants were randomly allocated to one of the 4
groups—Level 0: standard, nonpersonalized, dietary and PA
guidelines; Level 1: dietary and PA advice based on current
diet and PA; Level 2: dietary and PA advice based on current
diet, PA, and phenotype (eg, waist circumference and blood
cholesterol); and Level 3: dietary and PA advice based on
current diet, PA, phenotype, and genotype (eg, FTO). The
randomization scheme has been described previously [18]. All
data were collected remotely following standardized operating
procedures. At baseline, participants received study kits by post
containing all necessary materials, such as an accelerometer
and DNA collection kit (see the Physical Activity Assessment
and Genotyping sections below), to perform measurements at
home, but used their own scales to measure body weight. Printed
instructions were included and demonstration videos were
available on the Food4Me website [18,21].
On the allocated study day and following an 8-hour overnight
fast, participants collected a buccal cell sample for DNA;
measured their height, weight, and waist circumference; and
started wearing an accelerometer. The buccal cell sample was
returned to the research center in a prepaid stamped addressed
envelope and anthropometric measurement values were
self-reported online. Questionnaires to be completed online the
same day included the Baecke PA questionnaire (see the
Physical Activity Assessment section below). Participants
repeated the measurements, except DNA collection, at 3 and 6
months [18].
Following measurements at baseline and 3 months, participants
received, at both time points, a personalized (Levels 1-3) or
nonpersonalized (Level 0) report, including feedback on PA
according to their group. The personalized feedback provided
was based on a predefined set of algorithms, including
anthropometric, PA (Levels 1-3), phenotypic (Levels 2 and 3),
and genotypic (Level 3 only) data. Results in the personalized
report were compared with recommendations for each
anthropometric, PA (Levels 1-3), and phenotypic (Levels 2 and
3) item, using 3-color graded lines—green: good; amber:
improvement recommended; and red: improvement strongly
recommended. In addition, Level 3 participants received
information in their report about 5 diet- and lifestyle-related
genes [18]. For FTO, the message was “A specific variation of
this gene is associated with a greater need to maintain a healthy
body weight and engage in physical activity. A healthy weight
combined with exercise may provide added health benefits for
these individuals.” Participants were informed whether they
were carriers of the risk variant for the FTO SNP rs9939609
(yes or no, if they were genotyped AA or AT, or TT,
respectively). Each personalized report (Levels 1-3) also
contained a specific message related to body weight and PA.
Additionally, for Level 3 participants this specific message
referred to FTO. For example, for an AA/AT participant with
increased body mass index (BMI), increased waist
circumference, and low PA, the message was “We recommend
reducing your body weight and waist circumference to a healthy
normal range because you have a genetic variation that can
benefit by reducing these 2 obesity markers. Also, your physical
activity level is too low.” Full details of the study design have
been published elsewhere [18].
Physical Activity Assessment
Objective Physical Activity
PA was assessed objectively using the TracmorD triaxial
accelerometer (Philips Consumer Lifestyle, the Netherlands)
[22,23]. Participants were instructed to wear the accelerometer
every day while awake, except when taking a shower, for the
entire duration of the 6-month study. Participants uploaded data
every 2 weeks onto the study server via the Internet. Data were
recorded with a time-sampling interval of 1 min. A day was
considered valid if the participant had worn the TracmorD
accelerometer between 10 and 18 h. Wear time was defined as
24 h minus nonwear time. To define nonwear time, we adapted
the recommendations of Choi et al [24] to the TracmorD
accelerometer. R software version 3.1.2 (The R Foundation)
[25] was used for PA data processing.
Daily PA level (PAL)—the ratio of total energy expenditure to
basal metabolic rate—was derived from activity counts [22].
Time spent in sedentary behavior—corresponding to <1.5
metabolic equivalents (METs)—and moderate- and
vigorous-intensity PA—3 to <6 METs and ≥6 METs,
respectively—were calculated based on the application of
thresholds for activity energy expenditure (AEE) equivalent to
the METs thresholds. Daily AEE was calculated as follows:
Daily AEE = (0.9 × daily PAL - 1) × BMR (1)
where the daily basal metabolic rate (BMR) is estimated using
the Oxford equations developed by Henry, based on sex, age,
and weight [26].
PA estimates were calculated over a 2-week period at baseline
and 6 months. This 2-week assessment period occurred before
any feedback was given for the corresponding time point.
Sufficient PA data at each time point was defined as having at
least 3 valid weekdays and 2 valid weekend days of
accelerometer wear during the 2-week period. For individuals
with sufficient PA data, mean data per day were calculated
based on all valid week and weekend days of the assessment
period as follows:
Mean = (mean for weekdays × 5 + mean for weekend days ×
2) / 7 (2).
For sedentary time and time spent in moderate PA and vigorous
PA, weekly estimates were calculated as follows:
Mean = (mean for weekdays × 5 + mean for weekend days ×
2) (3).
Self-Reported Physical Activity
At each time point, participants completed the Baecke
questionnaire online [27] based on their PA during the last
month. This short, extensively validated questionnaire [28-30]
is composed of 3 sections—work, sport, and nonsport
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leisure—with indices ranging from 1 to 5 and a sum total (ie,
total activity index) ranging from 3 to 15. Scores were calculated
at baseline and month 6, according to the questionnaire protocol
[27].
Genotyping
Participants collected a buccal cell sample at baseline, using
Isohelix SK-1 DNA buccal swabs and Isohelix Dri-capsules
(LGC Genomics, Hertfordshire, UK). Samples were returned
to the recruiting centers and shipped to LGC Genomics, who
extracted the DNA and used competitive allele-specific
polymerase chain reaction (KASP) genotyping assays to provide
biallelic scoring of SNP rs9939609 in the FTO gene.
Statistical Analyses
Data are presented as means (SD) for continuous variables and
as percentages for categorical variables, unless otherwise stated.
A chi-square test was used to test if the observed FTO genotype
counts were in Hardy-Weinberg equilibrium [31]. To examine
if there was an association between PA and FTO genotype, we
used baseline data and robust multiple linear regression models,
based on computation of SMDM estimates [32] to account for
violation of the normality assumption. FTO genotype was
operationalized as risk (AA and AT) and nonrisk (TT).
To study the impact of knowledge of FTO risk status on changes
in PA, we used two approaches. In the first approach or primary
analysis, we investigated whether personalized advice based on
genetic information (ie, FTO risk) was more effective at
increasing PA than personalized advice without genetic-based
information in FTO risk and nonrisk carriers. In this analysis,
we compared Level 3 participants who received personalized
advice to increase PA, including disclosure of FTO risk, with
participants who received personalized advice to increase PA
without any genetic-based information (pooled Levels 1 and
2). As a secondary analysis, we assessed whether personalized
advice based on genetic information (ie, FTO risk) was more
effective at increasing PA than standard guidelines (ie,
nonpersonalized advice) in FTO risk and nonrisk carriers. This
analysis compared Level 3 participants with the control
group—Level 0, nonpersonalized guidelines. In order to match
the characteristics of both groups, participants in the control
group were included only if they had insufficient baseline PA
(ie, they would have been advised to increase their PA if they
had not been in the control group). For both primary and
secondary analyses, we used robust multiple regression models,
including an interaction term between FTO risk (yes or no) and
disclosure of genetic information (yes or no). If there was no
significant interaction, we looked at the main effects after
removing the interaction term from the model. Models were
adjusted for age, sex, country, BMI, season, accelerometer wear
time, and baseline PA variable as appropriate. Additional
sensitivity analyses were run, stratifying by sex and by tertile
of baseline PA variables. Attrition rates between groups were
compared using Pearson’s chi-square tests. R software version
3.1.2 (The R Foundation) [25] was used to perform all analyses
and the significance level was set at P<.05.
Results
Attrition Rate and Compliance
A total of 1607 individuals were randomized into the study (see
Figure 1) and 127 (7.90%) of them dropped out before starting
the trial; their characteristics will be reported elsewhere.
Genotype and PA data were available for 1279 of the 1480
(86.42%) starters, which were therefore included in the baseline
analysis (see Figure 1). Although sufficient accelerometer data
were defined as having a minimum of 3 valid weekdays and 2
valid weekend days of accelerometer wear, 77.56% (992/1279)
of subjects had 10 or more valid days of accelerometer wear at
baseline—mean 11.3 days (SD 2.4): 8.2 weekdays (SD 1.9) and
3.2 weekend days (SD 0.8).
Among the 1120 participants who received personalized advice
(Levels 1-3), 807 (72.05%) were advised to increase their PA
following assessment of baseline PA. Similarly, in the control
group (Level 0), 276 of 360 (76.7%) participants would have
been advised to increase their PA if the algorithms applied to
Levels 1-3 had been applied to the control group (see Figure
1). For these participants with inadequate PA, attrition rate was
similar between groups (14-15%, P=.45) at month 6 (see Figure
1). In the group where FTO risk was disclosed (Level 3),
participants with the nonrisk (TT) genotype were more likely
to drop out of the intervention than the at-risk (AA/AT)
participants—attrition rate 22% (TT) versus 12% (AA/AT);
odds ratio (OR) 2.04, 95% CI 0.96-4.29, P=.04. This was also
the case when considering all participants in Level 3 (ie, not
only those advised to increase their PA)—attrition rate 20%
(TT) versus 11% (AA/AT); OR 2.17, 95% CI 1.13-4.17, P=.01
(see Table 1). There were no significant differences in attrition
rates after 6 months between risk and nonrisk carriers in any
other groups.
Although only 157 out of 1083 (14.50%) participants with
inadequate PA had dropped out by month 6, compliance with
wearing the accelerometer decreased during the study. Thus,
46.45% (503/1083) of subjects had data on FTO genotype,
objective PA, and self-reported PA for both baseline and month
6, and were included in the analyses on change in PA (see Figure
1). Of these, 85.5% (430/503) and 68.0% (342/503) had 10 days
of valid accelerometer wear at baseline and month 6,
respectively. Mean number of valid days of accelerometer wear
for these participants was 11.9 days (SD 2.1) at baseline—8.6
weekdays (SD 1.7) and 3.3 weekend days (SD 0.7)—and 10.4
days (SD 3.0) at month 6—7.7 weekdays (SD 2.3) and 2.7
weekend days (SD 1.1). This was similar for all intervention
groups (data not shown for Levels 0-3).
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Table 1. Attrition rates after 6 months by intervention level.
Personalized and gene-based
advice
Personalized, nongene-based adviceStandard guidelinesGroup characteristics
Level 3Level 2Level 1Level 0
AA/ATTTAA/ATTTAA/ATTTAA/ATaTTa
257113255117244127247112Participants, n
27 (10.5)b23 (20.4)b38 (14.9)11 (9.4)40 (16.4)19 (15.0)34 (13.8)13 (11.6)Dropouts, n (%)
aTT and AA/AT are the nonrisk and risk genotypes, respectively, for the fat mass- and obesity-associated (FTO) rs9939609.
bSignificant difference in attrition rate between FTO TT and AA/AT genotypes for Level 3 participants (P=.01).
Figure 1. Flowchart of study procedures. Participants in Level 0 (controls) received standard, nonpersonalized guidelines during the intervention,
whereas participants in Levels 1-3 received personalized advice. PA: physical activity; FTO: fat mass- and obesity-associated gene.
Physical Activity and FTO Genotype
The characteristics of the 1279 participants with baseline PA
data both from accelerometers and self-reports, as well as data
on FTO genotype, are presented in Table 2. Most participants
were white, 743 (58.09%) were women, and 588 (45.97%) were
overweight or obese. Genotype frequency for FTO rs9939609
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did not deviate from Hardy-Weinberg equilibrium (TT=405, TA=641, and AA=233; P=.48).
Table 2. Characteristics of the participants included in baseline analysis.
FTOarisk statusOverall (n=1279)Variables
Nonrisk (TT)
(n=405)
Risk (AA/AT)
(n=874)
391 (96.5)848 (97.0)1239 (96.87)Ethnicity (white), n (%)
223 (55.1)520 (59.5)743 (58.09)Sex (women), n (%)
40 (13)40 (13)40 (13)Age in years, mean (SD)
1.72 (0.09)1.71 (0.09)1.71 (0.09)Height (m), mean (SD)
73.9 (15.2)75.2 (16.1)74.8 (15.8)Weight (kg), mean (SD)
25.0 (4.5)25.7 (4.9)25.5 (4.8)BMIb(kg/m2), mean (SD)
109 (26.9)270 (30.9)379 (29.63)Overweight (BMI 25.0-29.9 kg/m2), n (%)
53 (13.1)156 (17.8)209 (16.34)Obese (BMI ≥30.0 kg/m2), n (%)
14.4 (1.0)14.4 (1.1)14.4 (1.1)Accelerometer wear time (hours), mean (SD)
11.3 (2.4)11.3 (2.4)11.3 (2.4)Number of valid days, mean (SD)
Participants per season, n (%)
111 (27.4)266 (30.4)377 (29.48)Winter
240 (59.3)480 (54.9)720 (56.29)Spring
26 (6.4)73 (8.4)99 (7.74)Summer
28 (6.9)55 (6.3)83 (6.49)Autumn
Participants per country, n (%)
58 (14.3)116 (13.3)174 (13.60)Germany
50 (12.3)124 (14.2)174 (13.60)Greece
55 (13.6)123 (14.1)178 (13.92)Ireland
66 (16.3)148 (16.9)214 (16.73)The Netherlands
47 (11.6)130 (14.9)177 (13.84)Poland
60 (14.8)121 (13.8)181 (14.15)Spain
69 (17.0)112 (12.8)181 (14.15)United Kingdom
N/AN/Ac
233/641/405
(18.22/50.12/31.67)FTO genotype: AA/AT/TT, n (%)
aFTO: fat mass- and obesity-associated gene.
bBMI: body mass index.
cN/A: not applicable.
We found no association between objectively measured PAL
(P=.35), moderate PA (P=.28), vigorous PA (P=.24), or
sedentary time (P=.71) at baseline and FTO risk status (see
Figure 2, section a). Similarly, there was no significant
difference in baseline self-reported PA between risk and nonrisk
carriers (P=.76) (see Figure 2, section b).
Primary Analysis: Effect of Disclosing FTO Genotype
Status on Change in Physical Activity
Table 3 displays the PA characteristics of genotyped participants
advised to increase their PA at baseline, with objective PA and
self-reported PA data at baseline and month 6.
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Figure 2. Physical activity in FTO rs9939609 risk (AA/AT, n=874) and nonrisk (TT, n=405) carriers. FTO: fat mass- and obesity-associated gene.
J Med Internet Res 2016 | vol. 18 | iss. 2 | e30 | p.7http://www.jmir.org/2016/2/e30/
(page number not for citation purposes)
Marsaux et alJOURNAL OF MEDICAL INTERNET RESEARCH
XSL•FO
RenderX
Table 3. Changes in physical activity (PA) from baseline to month 6 for participants receiving personalized advice to increase their PA.
Nondisclosure (Levels 1 and 2)Disclosure (Level 3)Variables
FTO nonrisk TT
(n=78),
mean (SD)
FTO risk AA/AT
(n=160),
mean (SD)
FTO nonrisk TT
(n=39),
mean (SD)
FTOarisk AA/AT
(n=91),
mean (SD)
Objective PA b
Daily PAL c
1.67 (0.10)1.68 (0.10)1.67 (0.08)1.64 (0.10)Month 0
1.70 (0.17)1.70 (0.14)1.70 (0.13)1.66 (0.14)Month 6
Moderate PA (min/week)
189 (112)199 (111)209 (98)174 (124)Month 0
221 (130)218 (145)249 (120)206 (146)Month 6
Vigorous PA (min/week)
49 (64)54 (73)48 (67)37 (54)Month 0
61 (91)64 (93)57 (89)49 (76)Month 6
Sedentary time (min/week)
5433 (485)5327 (505)5391 (479)5449 (483)Month 0
5139 (579)5172 (541)5153 (449)5271 (606)Month 6
Self-reported PA: total activity index
7.69 (1.30)7.49 (1.37)7.51 (1.31)7.46 (1.49)Month 0
7.99 (1.44)7.84 (1.29)7.89 (0.99)8.00 (1.37)Month 6
aFTO: fat mass- and obesity-associated gene.
bPA: physical activity.
cPAL: physical activity level.
There was no significant interaction between disclosure of
genetic information and FTO risk status on change in objectively
measured or self-reported PA (all P>.25); this is illustrated in
Figure 3. There was also no effect of knowledge of FTO
genotype on objectively measured or self-reported PA (all
P>.10) (see Table 3 and Figure 3).
Secondary Analysis: Personalized Feedback Including
Disclosure of Genetic Information Compared With
Standard Guidelines
Comparisons between participants in the highest level of
personalization (Level 3) who were advised to increase their
PA, and control participants (Level 0) who would have been
advised to increase PA if they had been in a personalized group,
are given in Multimedia Appendix 2. There were no significant
interactions between intervention levels and FTO risk status on
change in PA. Change in objectively measured PA did not differ
significantly between Level 3 and Level 0 participants for both
risk and nonrisk carriers. However, Level 3 participants,
irrespective of FTO risk status, had greater changes in
self-reported PA than Level 0 participants (see Multimedia
Appendix 2).
Sensitivity Analyses
Results and conclusions were similar when carrying out the
analyses in men and women separately or after stratifying
analyses by tertile of baseline PA variables (data not shown).
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Figure 3. Effect of knowledge of FTO risk status on change in physical activity (PA) in risk (AA/AT) and nonrisk (TT) carriers. Nondisclosure FTO
risk carriers, n=160; nondisclosure FTO nonrisk carriers, n=78; disclosure FTO risk carriers, n=91; disclosure FTO nonrisk carriers, n=39. FTO: fat
mass- and obesity-associated gene.
Discussion
Principal Findings
Our main findings identified that there was no association
between objectively measured or self-reported PA and FTO risk
status. To our knowledge, our study is the first to investigate
the impact of FTO genotype-based feedback on measured
change in PA in the context of a personalized lifestyle
intervention. We hypothesized that knowledge of carriage of
FTO risk would lead to an increase in PA. However, we found
no evidence that disclosing such information had any positive
or negative effects on PA after a 6-month intervention.
Comparison With Previous Work
In the last decade, there has been a growing interest in
personalizing lifestyle interventions using genetic tests. This
has been done using DNA-based disease risk estimates,
primarily in smokers or individuals at risk of certain conditions,
such as Alzheimer’s disease [8]. The hope was that providing
such genetic information would motivate recipients to make
beneficial behavioral changes beyond what could be achieved
without such information. It is unclear whether knowledge of
being predisposed to a greater genetic risk of disease would
promote positive behavioral change and whether knowledge of
only a small genetic risk (ie, a "lower" genetic risk)
predisposition would lead to counterproductive behaviors under
false reassurances [33]. In their 2010 review, Marteau et al
reported no effect of adding DNA-based disease risk estimates
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compared with a non-DNA-based approach, in terms of smoking
cessation, PA, or use of medication/vitamins. A beneficial effect
of DNA-based risk estimates on dietary behavior was reported,
although no benefit on intention to change dietary behavior was
observed [8]. Since then, Hollands et al also observed no effect
of communicating DNA-based risk assessments for Crohn's
disease on smoking cessation, compared with standard risk
assessment [34]. Grant et al reported that diabetes genetic risk
counseling did not alter self-reported motivation or adherence
to a prevention program in overweight individuals at risk for
diabetes [35]. Although the design of our study was different
because we did not aim to recruit individuals specifically at risk
of a certain disease, our results are in line with the results of
most studies performed so far. Recently, Meisel et al showed
that young healthy individuals receiving FTO feedback in their
weight control advice felt more prepared to control their weight
than subjects receiving weight control advice only. However,
this did not translate into behavioral change [36].
Evidence in favor of disclosing genetic information is thus
limited. Even the favorable findings for dietary behavior change
mentioned above in the review by Marteau et al are weak [8].
They are based on only 2 studies [37,38], which did not find
significant effects when each study was evaluated individually.
More recently, Nielsen et al concluded that disclosing genetic
information for personalized nutrition resulted in greater
improvements in intake of some dietary components compared
with general population-based dietary advice. In reality, this
was true only for sodium intake, but not for caffeine, vitamin
C, or added sugars, which were also studied. In addition, only
individuals with the high-risk genotype status for the ACE gene
reduced their sodium intake more than controls based on
self-reported food intake, not on objective biomarkers of intake
[39]. Similarly, Hietaranta-Luoma et al reported that personal
genetic information based on ApoE might have positive effects
on triglyceride values and waist circumference, but this was
observed only in the high-risk ε4+ individuals [40].
Data suggest that providing genetic test results indicating a
higher genetic risk does not lead to fatalism [8]. Furthermore,
there is no indication that disclosing only a small genetic risk
or a lower-risk test result promotes counterproductive behaviors.
Similarly, in our study we found no differences in change in
PA between individuals aware of their nonrisk FTO status and
individuals aware of a risk, or not aware of their genotype.
However, we did observe that the attrition rate was significantly
greater among individuals informed of their nonrisk FTO status
as compared to the other groups. Given the amount and variety
of information provided to participants during the Food4Me
study, it seems unlikely that this genetic information would be
responsible for the higher number of dropouts. Nonetheless,
this should be studied further, as it may indicate that such
individuals felt the intervention was less relevant for them.
Grant et al also reported that subjects receiving lower-risk
genetic results showed lower intent to do exercise compared
with controls, although there were no differences in terms of
attendance to the diabetes prevention program [35].
Personalized feedback led to greater improvements in
self-reported PA, but not objectively measured PA, compared
with standard guidelines, as reported previously [19].
Discrepancies between self-reported and objectively measured
PA have been noted by others. For instance, Wanner et al, in a
Web-based tailored PA intervention, reported some
improvements in self-reported PA after 6 weeks and 13 months
of follow-up, but no differences between individuals in tailored
and control groups, and no improvement in objectively measured
PA for any group [41]. However, in our study we did find
greater improvements in self-reported PA in tailored groups as
compared with the controls. It could be that participants desired
to comply with recommendations and that receiving more
personalized feedback (Levels 2 and 3) increased this desire
further. Furthermore, here we show that the bigger
improvements in self-reported PA reported earlier are
irrespective of FTO genotype, and are not related to knowing
one’s risk status for FTO. Thus, it is unlikely that subjects with
the high-risk variant would feel more pressured to report that
they did better, compared with those with the low-risk variant.
Finally, we did not observe an association between FTO risk
and PA measured objectively or self-reported. This supports
studies published thus far that have used mainly self-reported
data [15,42,43].
Strengths and Limitations
This study is the first to report the impact of disclosing
information on FTO risk status on measured changes in PA.
Our PA questionnaire has been validated against doubly labeled
water and accelerometry [27,30,44], and has been used in large
European cohorts before [45,46]. However, self-reports
introduce large measurement error [47] and the Baecke
questionnaire is no exception [48]. Thus, a strength of this study
was the objective assessment of PA using triaxial
accelerometers. Although accelerometers underestimate certain
activities, such as cycling, swimming, or resistance training,
the TracmorD model used in this study has been validated
against doubly labeled water [22] and it has been shown to be
reliable and accurate [49-51].
By design, we recruited individuals interested in taking part in
a personalized intervention on nutrition and lifestyle, which is
less representative than a European-wide survey. Nonetheless,
our participants were broadly representative of the European
adult population, most of whom had adequate nutrient intakes
but could benefit from improved dietary choices and greater
PA [52]. Given that Food4Me was an intervention that targeted
multiple dietary and lifestyle behaviors, the genetic results might
have also been diluted by the amount of information provided.
Moreover, the genetic feedback was a positive reinforcement.
Participants with the higher-risk genotype would only benefit
more by reducing their weight or increasing their PA. It is
possible that the impact would have been greater if participants
had been made more aware of the links between obesity and
lifelong ill health. Furthermore, genetic feedback provided by
health professionals skilled in genetic counseling might have
been more effective that written feedback. However, this would
have been more expensive and outside the scope of this study,
which was designed to test the effects of an Internet-delivered
intervention. Such interventions are thought to offer considerable
advantages in terms of reach, scalability, and sustainability [53].
Attrition rates (~15%) were as expected and compliance with
the measurements was good, except for wearing the monitor.
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Only half of the participants had accelerometer data for both
baseline and month 6—whereas >75% had self-reported PA
data at both time points—which limited the size of the sample
analyzed in the PA analyses. It is possible that wearing the
monitor for 6 months was too demanding for the amount of
feedback given. It may be important for future studies that
participants be able to visualize their activity levels, in real time,
whenever desired (eg, on an accompanying website).
Improvements in activity measurement may reduce participants’
confusion and/or frustration. Having personalized coaches
available, who can also operate online, may have motivated
participants to wear their accelerometer and to improve their
PA, although this also means extra costs. For the sole purpose
of assessment, better compliance may be obtained by sending
out monitors and collecting them back directly after assessment
[54]. In spite of this, our sample size was acceptable, and the
results did not change when looking at all self-reported PA data
available.
Conclusions
There was no added benefit of knowledge of FTO risk on change
in PA in this intervention study. Although there were no
differences in outcome measures between participants informed
of a nonrisk and those informed of a risk, or those not informed
of their FTO risk status, the nonrisk subjects were more likely
to drop out of the study by 6 months. More studies are needed
to confirm whether disclosure of lower-risk genetic test results
has adverse effects on engagement in behavioral changes. Before
that, more effort should be devoted to identify the features
necessary to engage individuals, how to frame the feedback,
and how to coach effectively, especially those at risk, to reduce
health inequalities.
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